LBA52Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC). (23rd October 2018) - Wolf, J; Seto, T; Han, J-Y; Reguart, N; Garon, E B; Groen, H J M; Tan, D S; Hida, T; de Jonge, M J A; Orlov, S V; Smit, E F; Souquet, P-J; et al.